AU2018283348A1 - IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury - Google Patents

IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury Download PDF

Info

Publication number
AU2018283348A1
AU2018283348A1 AU2018283348A AU2018283348A AU2018283348A1 AU 2018283348 A1 AU2018283348 A1 AU 2018283348A1 AU 2018283348 A AU2018283348 A AU 2018283348A AU 2018283348 A AU2018283348 A AU 2018283348A AU 2018283348 A1 AU2018283348 A1 AU 2018283348A1
Authority
AU
Australia
Prior art keywords
markers
tbi
protein
fabp
mtbi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018283348A
Other languages
English (en)
Inventor
Jean-Charles Sanchez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Geneva
Original Assignee
University of Geneva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Geneva filed Critical University of Geneva
Publication of AU2018283348A1 publication Critical patent/AU2018283348A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2018283348A 2017-06-15 2018-06-07 IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury Abandoned AU2018283348A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17001015.1 2017-06-15
EP17001015 2017-06-15
PCT/EP2018/065090 WO2018228927A1 (en) 2017-06-15 2018-06-07 Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury

Publications (1)

Publication Number Publication Date
AU2018283348A1 true AU2018283348A1 (en) 2020-01-02

Family

ID=59091305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018283348A Abandoned AU2018283348A1 (en) 2017-06-15 2018-06-07 IL-10, S100B and H-FABP markers and their use in detecting traumatic brain injury

Country Status (6)

Country Link
US (1) US20200174015A1 (cg-RX-API-DMAC10.html)
EP (1) EP3639034A1 (cg-RX-API-DMAC10.html)
JP (1) JP2020525765A (cg-RX-API-DMAC10.html)
CN (1) CN110770586A (cg-RX-API-DMAC10.html)
AU (1) AU2018283348A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018228927A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113366318A (zh) * 2019-01-31 2021-09-07 日内瓦大学 创伤性脑损伤(tbi)的前瞻性标志物
CN115170540B (zh) * 2022-07-26 2025-07-11 浙江工业大学 一种基于多模态影像特征融合的轻度创伤性脑损伤分类方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008819A2 (en) * 2006-07-11 2008-01-17 University Of Florida Research Foundation, Inc. Diagnosis and treatment of neurological inflammation
US20120322682A1 (en) * 2011-06-20 2012-12-20 William Marsh Rice University Brain injury biomarker panel
CA2943396A1 (en) * 2014-04-07 2015-10-15 Iron Horse Diagnostics, Inc. Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
EP3702786A1 (en) * 2014-10-06 2020-09-02 Université de Genève Markers and their use in brain injury

Also Published As

Publication number Publication date
WO2018228927A1 (en) 2018-12-20
CN110770586A (zh) 2020-02-07
US20200174015A1 (en) 2020-06-04
JP2020525765A (ja) 2020-08-27
EP3639034A1 (en) 2020-04-22

Similar Documents

Publication Publication Date Title
US20200110100A1 (en) Markers and their use in brain injury
Mahan et al. Glial fibrillary acidic protein (GFAP) outperforms S100 calcium-binding protein B (S100B) and ubiquitin C-terminal hydrolase L1 (UCH-L1) as predictor for positive computed tomography of the head in trauma subjects
Chabok et al. Neuron-specific enolase and S100BB as outcome predictors in severe diffuse axonal injury
US12422442B2 (en) Markers and their use in brain injury
US20120149042A1 (en) Methods for predicting outcome in traumatic brain injury
Whistler et al. Integration of gene expression, clinical, and epidemiologic data to characterize Chronic Fatigue Syndrome
Puravet et al. Can the association of the biomarkers GFAP and UCH-L1 predict intracranial injury after mild traumatic brain injury in adults? A systematic review and meta-analysis
Wang et al. Evaluation of serum matrix metalloproteinase-3 as a biomarker for diagnosis of epilepsy
KR20180083909A (ko) 알츠하이머병의 진단 또는 예측, 또는 파킨슨병의 진단을 위한 락토페린
EP3887831A1 (en) Methods, systems, and a kit for diagnosis, detection, monitoring and treatment of traumatic brain injury
US20200174015A1 (en) Il-10, s100b and h-fabp markers and their use in detecting traumatic brain injury
US20110236917A1 (en) Diagnosis of Alzheimer's Disease
Waliullah et al. Serum S100-Beta as a biomarker for neurological recovery in Acute Spinal Cord Injury (ASCI): A prospective case-control study
Delefortrie et al. Evaluation of the Roche® Elecsys and the Diasorin® Liaison S100 kits in the management of mild head injury in the emergency room
EP3918336A1 (en) Prospective markers in traumatic brain injury (tbi)
Li et al. Microglial/macrophage activation in the cerebrospinal fluid of neuromyelitis optica spectrum disorders
US20190346458A1 (en) Gfap accumulating in stroke
US20210293831A1 (en) Method of Performing Differential Diagnosis of Neurodegenerative Diseases in a Subject
Brennan Utility Of Plasma Biomarkers In The Validation Of Reported Loc & Pta For Gcs 13-15 Patients: A Track-Tbi Pilot Study
Zou et al. Serial assessment of the novel biomarker MFGE8 in comparison with GFAP for predicting severity and outcome after traumatic brain injury
Fakharian et al. A study on the predictive value of glial fibrillary acidic protein for prediction of traumatic brain injury severity
Çelikel et al. Evaluation of NSE and GFAP level and hemorrhage volume in terms of prognosis in head trauma: A prospective controlled study.
CN119738566A (zh) 新喋呤在无症状神经梅毒检测中的应用
KR20260006588A (ko) 경도인지장애 및 알츠하이머병에 대한 단백질 마커
GALHOM et al. Serum S100 Protein as a Predictor of Long Term Outcome in Mild and Moderate Traumatic Brain Injury

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application